Tremfya is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis.

The overactive immune response in psoriasis can influence your brain’s chemicals, which can lead to both depression and ...

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Psoriasis is a chronic inflammatory skin condition characterized ... meta-analysis found topical honey to be an effective treatment for plaque psoriasis and mild-to-moderate scalp psoriasis.

Prof. Adam Reich reviewed itch in psoriasis, while Dr. Anushka Irani discussed the connection between pain and psoriatic ...

Tremfya, a monoclonal antibody that blocks IL-23, is also approved to treat patients with plaque psoriasis and active ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

Psoriasis is a common chronic inflammatory skin disease affecting ... well-tolerated, non-steroidal treatment option to the millions of people living with plaque psoriasis and potentially atopic ...